NCT01834729View on ClinicalTrials.gov

Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

PHASE2CompletedINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 6, 2017

Study Completion Date

September 6, 2017

Conditions

Constipation

Interventions

DRUG

Alfuzosin

oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)

OTHER

Placebo

placebo capsule identical to the study drug

Trial Locations (1)

55905

Mayo Clinic Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT01834729 - Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions | Biotech Hunter | Biotech Hunter